350 rub
Journal №8 for 2014 г.
Article in number:
Interleukines in blood serum of patients with bone tumors
Keywords: IL-16 IL-2 bone tumors
Authors:
I.V. Babkina - Dr.Sc. (Med.), Professor, Moscow State University of Medicine and Dentistry n. a. A.I. Evdokimov. E-mail: biochimia@mtu-net.ru
Yu.S. Timofeev - Physician Clinical Laboratory Diagnosis, Russian Cancer Research Center of N.N. Blokhin Russian Academy of Medical Sciences, Moscow, Russia
I.N. Kuznetsov - Ph.D.(Biol.), Moscow State University of Medicine and Dentistry n. a. A.I. Evdokimov
D.V. Rogozin - Ph.D. (Med.), Head of Pathology Department, Russian Children-s Clinical, Moscow, Russia
E.Yu. Russo - Post-graduate Student, Moscow State University of Medicine and Dentistry n. a. A.I. Evdokimov
Z.G. Kadagidze - Dr.Sc. (Med.), Moscow State University of Medicine and Dentistry n. a. A.I. Evdokimov
Yu.N. Soloviev - Dr.Sc.(Med.), Professor, Academician RAS, Russian Cancer Research Center of N.N. Blokhin Russian Academy of Medical Sciences, Moscow, Russia
Abstract:
Progress in the treatment of cancer and bone tumors including associated with a significant breakthrough in molecular biology, immunology, understanding the causes of tumor cells and patterns of development of the tumor process. The results of studies of interleukins (IL-16, IL-2) by ELISA in the serum of patients with primary malignant bone tumors and healthy age-matched to identify the possible correlation with the histological structure of the tumor. It is shown that the detection rate of IL-16 in serum in bone tumors was 93%, no significant differences in levels of IL-16 in considering the histological structure of tumor is not revealed. Relationship between the size of the primary tumor and the content of IL-16 in serum were found. Overall 3- and 5-year survival of patients with malignant bone tumors with IL-16 content in the blood serum of >33.0 pg/ml was significantly lower than patients with low levels of IL-16. Osteosarcoma overall 5-year survival in patients with high IL-16 in serum was 1.6 times, Ewing's sarcoma in 1.7 times, chondrosarcoma - 1.8 times lower than in patients with IL-16 content serum <33.0 pg/ml. IL-2 serum samples of healthy subjects was absent in all bone tumors in 1 patient (1.4%) without concomitant pathology revealed significant level of IL-2.
Pages: 23-28
References

  1. Berezhnaya N.M., Chexun V.F. Immunologiya zlokachestvennogo rosta // Kiev: Naukova dumka. 2005. 790 s.
  2. Lebedev K.A., Ponyakina I.D. Immunnaya nedostatochnost' (vy'yavlenie i lechenie) // M.: Mediczinskaya kniga. N.Novgorod: Izdatel'stvo NGMA. 2003. 443s.
  3. Anderson P. Non-surgical treatment of pulmonary and extra-pulmonary metastases // Cancer Treat. Res. 2009. V. 152. P. 203 - 215.
  4. Atanackovic D., Hildebrandt Y., Templin J. et al. Role of interleukin 16 in multiple myeloma // J. Natl. Cancer Inst. 2012. V. 104. № 13. P. 1005 - 1020.
  5. Cao Y., Luetkens T., Kobold S. et al. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients // Exp. Hematol. 2010. V. 38. № 10. P. 860 - 867.
  6. Compérat E., Rouprêt M., Drouin S.J. et al. Tissue expression of IL-16 in prostate cancer and its association with recurrence after radical prostatectomy // Prostate. 2010. V. 70. № 15. P. 1622 - 1627.
  7. Fagioli F., Biasin E., Mereuta O.M. et al. Poor prognosis osteosarcoma: new therapeutic approach // Bone Marrow Transplant. 2008. V. 41. Suppl. 2. S. 131 - 134.
  8. Gao L.B., Liang W.B., Xue H. et al. Genetic polymorphism of interleukin-16 and risk of nasopharyngeal carcinoma // Clin. Chim. Acta. 2009. V. 409. № 1 - 2. P. 132 - 135.
  9. Gao L.B., Rao L., Wang Y.Y. et al. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer // Carcinogenesis. 2009. V. 2. № 2. P. 295 - 299.
  10. Hamblin A.S. Lymphokines and interleukins // Immunology. 1988. S.1. P. 39 - 41.
  11. Kohyama K., Sugiura H., Kozawa E. et al. Antitumor activity of an interleukin-2 monoclonal antibody in a murine osteosarcoma transplantation model // Anticancer Res. 2012. V. 32. № 3. P. 779 - 782.
  12. Koike M., Sekigawa I., Okada M. et al. Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16 // Leuk. Res. 2002. V. 26. P. 705 - 711.
  13. Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy // Biomed. Pharmacother. 2001. V. 55. P. 111 - 116.
  14. Li S., Deng Y., Chen Z.P. et al. Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population // Infect. Genet. Evol. 2011. V. 11. № 8. P. 2083 - 2088.
  15. Mackall C.L., Rhee E.H., Read E.J. et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas // Clin. Cancer Res. 2008. V. 14. № 15. P. 4850 - 4858.
  16. Mahindra A., Anderson K.C. Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target - // J. Natl. Cancer Inst. 2012. V. 104. № 13. P. 964-965.
  17. Markiewicz K., Zeman K., Kozar A., Gołebiowska-Wawrzyniak M. Evaluation of selected cytokines in children and adolescents with osteosarcoma at diagnosis - preliminary report // Med. Wieku Rozwoj. 2011. V. 15. № 1. P. 25 - 31.
  18. Mathy N.L., Scheuer W., Lanzendörfer M. et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes // Immunology. 2000. V. 100. P. 63 - 69.
  19. Mc Tiernan A., Jinks R.C., Sydes M.R. et al. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup // Eur. J. Cancer. 2012. V. 48. № 5. P. 703 - 712.
  20. Moon M.H., Jeong J.K., Seo J.S. et al. Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation // Exp. Mol. Med. 2011. V. 43. № 3. P. 138 - 145.
  21. Rumsaeng V., Cruikshank W.W., Foster B. et al. Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16 // J. Immunol. 1997. V. 159. P. 2904 - 2910.
  22. Sharma V., Sparks J.L., Vail J.D. Human B-cell lines constitutively express and secrete interleukin-16 // Immunology. 2000. V. 99. P. 266 - 271.
  23. Thomas G., Jacobs K.B., Yeager M. et al. Multiple loci identified in a genome-wide association study of prostate cancer // Nat. Genet. 2008. V. 40. P. 310 - 315.
  24. Waldmann T.A. Multichain interleukin-2 receptor: a target for immunotherapy in limphoma // J. Natl. Cancer Inst. 1989. V. 81. № 12. P. 914 - 923.
  25. Yellapa A., Bahr J.M., Bitterman P. et al. Association of interleukin 16 with the development of ovarian tumor and tumor-associated neoangiogenesis in laying hen model of spontaneous ovarian cancer // Int. J. Gynecol. Cancer. 2012. V. 22. № 2. P. 199 - 207.
  26. Zhu J., Qin C., Yan F. et al. IL-16 polymorphism and risk of renal cell carcinoma: association in a Chinese population // Int. J. Urol. 2010. V. 17. № 8. P. 700 - 707.